To-date, Small to Medium Enterprises (SMEs) and Multinational Corporations (MNCs) have invested with REMODEL to address their research and development needs; co-develop a new product; assess the properties of medical devices under development in silico, in vitro and in preclinical models and conduct market research.
Supported by National and International funding schemes, REMODEL collaborates closely with industry partners on specific projects to develop the next generation of medical devices.
REMODEL’s technology licencing is supported by the Ignite – Technology Transfer Office at NUI Galway, ensuring appropriate intellectual property protection, management and licencing.
REMODEL personnel are frequently seconded to industry collaborators to address research and development questions in situ or to work on scalability of processes.
Industry personnel are frequently hosted at REMODEL to develop specific research and laboratory skills or to access REMODEL’s state of the art facilities.
REMODEL personnel engage with industries to advise on appropriate experimental work for specific clinical indications; to design future R&D strategies and to address questions raised during FDA device dossier submission.
REMODEL operates at the leading edge of medical device R&D, with an ethos and structure that promotes entrepreneurship and the development of innovative products and services for international markets in healthcare and the institutional infrastructure and support to spin-out developing technologies.